pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 8·1 min read
save

Medicare’s new RAPID coverage pathway speeds adult device access, but pediatric devices still lag

May 8, 2026·read at STAT ↗RegulatoryPositive

The Centers for Medicare and Medicaid Services and the FDA introduced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway. The new process promises Medicare national coverage within two months of FDA market authorization, a significant acceleration from the typical year-long wait.

Proponents say the RAPID pathway could remove a major reimbursement barrier for adult medical devices, allowing patients quicker access to innovative treatments. The author, a senior research scientist with experience guiding small companies through FDA review, welcomes the change as a needed step forward.

However, the announcement does not address the longstanding lag in pediatric and orphan device development. The author notes that children continue to face slower approval and coverage timelines, leaving a critical gap in care despite the broader regulatory improvement.

The piece calls for continued focus on pediatric device innovation to ensure that the benefits of faster coverage extend to all patient groups.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: STAT+: Medicare’s new RAPID pathway is a breakthrough for adults. Children are still waiting”

read at STAT ↗
455 words · retrieved May 8
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Rare Disease3Alzheimer's DiseaseApprovalCardiology

related stories

  • 48m agoEyepoint, Enlivex enact heavy layoffsBioSpace
  • Dec 23Fierce Biotech Layoff Tracker 2026: Enlivex excises 60%; Eyepoint halves headcountFierce Biotech
  • Jul 12STAT+: Tau in the spotlight at Alzheimer’s conferenceSTAT
  • Jul 10STAT+: Roche ends Huntington’s gene-silencing programsSTAT
  • Jul 10STAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and moreSTAT